Skip to main content

Advertisement

Fig. 2 | Clinical Epigenetics

Fig. 2

From: PITX3 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients after radical prostatectomy

Fig. 2

PITX3 DNA methylation in prostatectomy specimens. Median methylation is indicated by the gray line. PITX3 DNA methylation is significantly higher in prostate cancer (PCa) tissue compared to corresponding normal adjacent tissue (NAT) and benign prostatic hyperplasia (BPH). a NAT and PCa samples of the training cohort (TCGA). p values refer to Wilcoxon-Mann-Whitney test. b NAT, BPH, and PCa samples from a test study comprising 71 patient samples. Each sample was measured in triplicate. p values refer to Kruskal-Wallis test

Back to article page